> One of the primary vehicles for kickbacks and fraud seems to be foundations associated with federal agencies. The reason they’re so frequently used for questionable transactions is because foundations are private entities and not subject to Freedom of Information Act requests and other open records laws > The board of directors of the Foundation for the National Institutes of Health (FNIH) is heavily populated with Big Pharma players. This raises serious questions about conflicts of interest, as the foundation oversees the distribution of hundreds of millions of dollars — unregulated funds that typically go right back into the coffers of the drug industry > This conflict of interest also, at least in part, helps explain the actions of Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases (NIAID) and now-retired director of the NIH, Dr. Francis Collins. Both have gone out of their way to protect the makers of COVID shots and dismiss evidence that SARS-CoV-2 was created in and escaped from a lab > Dr. Julie Gerberding became the FNIH CEO March 1, 2022. She was formerly director of the U.S. Centers for Disease Control and Prevention. After leaving the CDC, she became the executive vice president of strategic communications at Merck > The FNIH’s board of directors includes seven current or former drug company executives, the FDA, the Sackler family (notorious for its creation of a deadly opioid epidemic), Johns Hopkins (co-sponsor of Event 201, which “predicted” COVID-19 and the subsequent destruction of human rights), and two major investment bankers, Goldman Sachs and BlackRock
One of the primary vehicles for kickbacks and fraud seems to be foundations associated with federal agencies. This article will highlight and expose yet another way we are being conned and manipulated by examining the Foundation for the National Institutes of Health1 (FNIH), whose board is plastered with major Big Pharma players.
This raises serious questions about conflicts of interest, seeing how the foundation oversees the distribution of hundreds of millions of dollars — unregulated funds that typically go right back into the coffers of the drug industry. It’s a very clever strategy to extract even more funds from the American taxpayers.
This conflict of interest also, at least in part, helps explain the actions of Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases (NIAID) and now-retired director of the NIH, Dr. Francis Collins.2 Both have gone out of their way to protect the makers of COVID shots and dismiss evidence that SARS-CoV-2 was created in and escaped from a lab.
FNIH Board — A Who’s Who of Big Pharma
In 2020, Fauci received the FNIH’s Charles A. Sanders MD Partnership Award for his leadership and support of “FNIH programs propelling research in lethal infectious diseases.”3
Dr. Charles Sanders was the FNIH chairman between 1996 and 2016. Before that, he was the chairman and CEO of Glaxo Inc. He also spent eight years with Squibb Corp., where he held several positions, including CEO of the Science and Technology Group.4 He’s currently a member of the FNIH board of directors.
In the video above, Fauci is interviewed by Dr. Freda Lewis-Hall about his career, his achievements and the public-private partnerships that allowed for the creation of Operation Warp Speed and the rapid deployment of a COVID-19 jab. Lewis-Hall is a former chief medical officer and executive vice president at Pfizer. She is also a current board member of the FNIH.
Another striking member of the FNIH’s board is Dr. Julie Gerberding. If you have a sharp memory for details, you may recall she served as director of the CDC from 2002 to 2009.
After resigning from the CDC, she entered the express revolving door between industry and government and was hired by Merck as their vice president in charge of vaccines. Imagine that — the head of the government agency responsible for policing vaccines is hired by one of the world’s largest producers of vaccines.
Sadly, it’s all perfectly legal. Later, she oversaw global public policy and strategic communications at Merck, followed by a position as chief patient officer and executive vice president for population health and sustainability.5 Gerberding has now taken her nefarious behavior to an entirely new level. She’s slid back through yet another revolving door and is the CEO of FNIH as of March 1, 2022.6 Other FNIH board members include: